Hyman, Phelps & McNamara, P.C.
Visit the Hyman, Phelps & McNamara, P.C. blog at www.fdalawblog.net
Size of Organization: 39
Year Established: 1980Web Site: http://www.hpm.com
|Profile Visibility |
#4,402 in weekly profile views out of 270,734 total law firms Overall
Hyman, Phelps & McNamara, P.C. is a law firm that advises and represents a broad range of clients on legal issues concerning food, drug, medical device and cosmetic law and regulation. To complement its core expertise in FDA matters, the firm also serves its clients in related areas, such as advertising, controlled substance regulation, health care fraud and abuse, reimbursement, pricing laws and government contracts. In 1980, three former U.S. Food and Drug Administration (FDA) lawyers opened the firm in Washington, D.C. to concentrate in this area of the law. Hyman, Phelps & McNamara, P.C. now has one of the most extensive food and drug practices in the United States.
Martindale-Hubbell has augmented a firm's provided information with third-party sourced data to present a more comprehensive overview of the firm's expertise:
U.S. Federal Litigation Activity
Highest number of cases by Hyman, Phelps & McNamara, P.C.:
Contracts (1 cases in past two years)
Peer Review Ratings
Total number of Peer Review Rated lawyers of Hyman, Phelps & McNamara, P.C.:
Documents by Hyman, Phelps & McNamara, P.C. on Martindale.com
FDA Speaks to Nanotech in Cosmetics, Foods, and Drugs
Ricardo Carvajal, May 22, 2013
April was a busy month for nanotechnology at FDA. The agency issued two draft guidance documents worthy of close examination for those with an interest in the use of emerging technologies, including nanotechnology, in the cosmetic and food industries. Further, FDA denied a citizen petition asking...
FSIS Finalizes Rules Mandated by the 2008 Farm Bill
Riëtte van Laack, May 22, 2013
On May 8, 2012, the Food Safety and Inspection Service (“FSIS”) published three sets of regulations mandated by the 2008 Farm Bill: (1) regulations requiring that meat and poultry plants promptly (within 24 hrs) notify FSIS that a contaminated or misbranded product has been released...
While We’re Waiting on Bartlett, Some New Preemption Challenges to Consider
Kurt R. Karst, May 21, 2013
As folks in the generic drug industry patiently await the U.S. Supreme Court’s decision in Mutual Pharmaceutical Co. v. Bartlett (Docket No. 12-142), a design defect generic drug preemption case (see our previous post here), we thought we would whet the preemption appetite with two new...